Recurrent heart failure hospitalizations increase the risk of cardiovascular and all‐cause mortality in patients with heart failure in Sweden: a real‐world study

Lindmark, Krister; Boman, Kurt; Stålhammar, Jan; Olofsson, Mona; Lahoz, Raquel; Studer, Rachel; Proudfoot, Clare; Corda, Stefano; Fonseca, Ana Filipa; Costa‐Scharplatz, Madlaina; Levine, Aaron; Törnblom, Michael; Castelo-Branco, Anna; Kopsida, Eleni; Wikström, Gerhard

doi:10.1002/ehf2.13296

Cited by 17 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is considered consistent when compared with a previous HF registry study. 27 However, other similar studies have shown mortality to be as low as 8.2%. 14 31 The difference is attributed to the fact that mortality in the present study is calculated from the first day of HF diagnosis, whereas comparable HF registry studies do not take the date of diagnosis into consideration.…”

Section: Discussionmentioning

confidence: 92%

Clinical characteristics and mortality of patients with heart failure in Southern Sweden from 2013 to 2019: a population-based cohort study

et al. 2022

View full text Add to dashboard Cite

ObjectivesTo describe clinical characteristics and prognosis related to heart failure (HF) phenotypes in a community-based population by applying a novel algorithm to obtain ejection fractions (EF) from electronic medical records.DesignRetrospective population-based cohort study.SettingData were collected for all patients with HF in Southwest Sweden. The region consists of three acute care hospitals, 40 inpatient wards, 2 emergency departments, 30 outpatient specialty clinics and 48 primary healthcare.Participants8902 patients had an HF diagnosis based on the International Classification of Diseases, Tenth Revision during the study period. Patients <18 years as well as patients declining to participate were excluded resulting in a study population of 8775 patients.Primary and secondary outcome measuresThe primary outcome measure was distribution of HF phenotypes by echocardiography. The secondary outcome measures were 1 year all-cause mortality and HR for all-cause mortality using Cox regression models.ResultsOut of 8775 patients with HF, 5023 (57%) had a conclusive echocardiography distributed into HF with reduced EF (35%), HF with mildly reduced EF (27%) and HF with preserved EF (38%). A total of 43% of the cohort did not have a conclusive echocardiography, and therefore no defined phenotype (HF-NDP). One-year all-cause mortality was 42% within the HF-NDP group and 30% among those with a conclusive EF. The HR of all-cause mortality in the HF-NDP group was 1.27 (95% CI 1.17 to 1.37) when compared with the confirmed EF group. There was no significant difference in survival within the HF phenotypes.ConclusionsThis population-based study showed a distribution of HF phenotypes that varies from those in selected HF registries, with fewer patients with HF with reduced EF and more patients with HF with preserved EF. Furthermore, 1-year all-cause mortality was significantly higher among patients with HF who had not undergone a conclusive echocardiography at diagnosis, highlighting the importance of correct diagnostic procedure to improve treatment strategies and outcomes.

show abstract

Section: Discussionmentioning

confidence: 92%

Clinical characteristics and mortality of patients with heart failure in Southern Sweden from 2013 to 2019: a population-based cohort study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There is a strong association between recurrent HFH and cardiovascular (CV) and all-cause mortality, with the risk increasing progressively with each recurrent HFH. 5 This increases the burden on the patient and the healthcare system.…”

Section: Impact Of Hf Hospitalization On Mortalitymentioning

confidence: 99%

Role of Iron Therapy in Heart Failure: A Consensus Statement from India

Chopra¹,

Wander²,

Nair³

et al. 2023

JAPI

View full text Add to dashboard Cite

Iron deficiency (ID) with or without anemia is frequently observed in patients with heart failure (HF). Uncorrected ID is associated with higher hospitalization and mortality in patients with acute HF (AHF) and chronic HF (CHF). Hence, in addition to chronic renal insufficiency, anemia, and diabetes, ID appears as a novel comorbidity and a treatment target of CHF. Intravenous (IV) ferric carboxymaltose (FCM) reduces the hospitalization risk due to HF worsening and improves functional capacity and quality of life (QOL) in HF patients. The current consensus document provides criteria, an expert opinion on the diagnosis of ID in HF, patient profiles for IV FCM, and correct administration and monitoring of such patients

show abstract

“…The number of HF hospitalizations is a strong predictor of cardiovascular (CV) and all-cause mortality [ 8 , 9 ].…”

Section: Do Patients With Advanced Heart Failure (Hf) Have a Need For...mentioning

confidence: 99%

Ten Questions and Some Reflections about Palliative Care in Advanced Heart Failure Patients

Romanò

2022

JCM

View full text Add to dashboard Cite

Heart failure is a clinical syndrome with increasing prevalence, high morbidity and mortality. It is characterized by high symptom burden, poor quality of life and high economic costs. This implies that the heart failure (HF) patients who receive palliative care (PC) have needs similar to cancer patients, but which are often unmet. This paper analyzes the main unresolved issues regarding the relationship between HF patients and the referral to an early PC program. These issues are presented as ten questions related to which patients should be admitted to PC and at what stage of their disease. Furthermore, the barriers opposing to referral to PC, the role of cardiologists and PC physicians within the care team, the gap between the scientific societies’ suggestions and the real world, the right time to promote patients’ awareness and shared decision making, regarding prognosis, end of life wishes and choices, with reference also to cardiac implantable devices’ deactivation, are discussed. These unresolved questions support the need to reevaluate programs and specific models in achieving equal access to palliative care interventions for HF patients, which is still mainly offered to patients with cancer.

show abstract

Recurrent heart failure hospitalizations increase the risk of cardiovascular and all‐cause mortality in patients with heart failure in Sweden: a real‐world study

Cited by 17 publications

References 22 publications

Clinical characteristics and mortality of patients with heart failure in Southern Sweden from 2013 to 2019: a population-based cohort study

Clinical characteristics and mortality of patients with heart failure in Southern Sweden from 2013 to 2019: a population-based cohort study

Role of Iron Therapy in Heart Failure: A Consensus Statement from India

Ten Questions and Some Reflections about Palliative Care in Advanced Heart Failure Patients

Contact Info

Product

Resources

About